Organovo to Present at 2018 Cell & Gene Meeting on the Mesa
September 26 2018 - 8:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology
company pioneering the development of 3D bioprinted tissues aimed
at treating a range of serious adult and pediatric liver diseases,
today announced that Chief Executive Officer, Taylor J. Crouch, is
scheduled to speak at the Cell & Gene Meeting on the Mesa to be
held October 3-5 in La Jolla, Ca.
This conference is the largest partnering meeting
organized specifically for the cell and gene therapy sector,
providing the opportunity for participants to establish key
relationships and accelerate business development.
Organized by ARM and the Sanford Stem Cell Clinical
Center at UC San Diego, the Cell & Gene Meeting on the Mesa is
a three-day conference featuring three distinct parts, the
program’s two-day Partnering Forum, a Public Forum lecture and a
full-day Scientific Symposium. The event’s Partnering Forum on
October 3-4 features more than 70 dedicated company presentations
in addition to over 90 panelists and featured speakers. This year’s
event is expected to attract more than 950 attendees, including
senior executives from leading cell therapy, gene therapy and
tissue engineering companies worldwide, large pharma and biotech,
institutional investors, academic research institutions, patient
foundations, disease philanthropies and life science media.
|
|
|
|
The
following are specific details regarding Organovo’s presentation at
the conference: |
|
|
|
|
|
Event: |
|
2018 Cell &
Gene Meeting on the Mesa – Partnering Forum |
|
|
|
|
|
Date: |
|
October 3, 2018 |
|
|
|
|
|
Time: |
|
4:00 p.m. Pacific Time
(PT) |
|
|
|
|
|
Location: |
|
Estancia La Jolla Hotel
& Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037 |
|
|
|
|
A live video webcast of all company presentations
will be available at http://www.meetingonthemesa.com/webcast and
will also be published on the conference website shortly after the
event.
About Organovo Holdings,
Inc.Organovo is a biotech platform company that has
developed a leadership position with its revolutionary ability to
3D bioprint tissues with human functionality. The Company is
pursuing multiple IND-track programs to develop its
NovoTissues® to address a number of serious unmet medical
needs in adult and pediatric populations, initially focusing on
liver disease. Organovo’s first IND-track program for
Alpha-1-antitrypsin deficiency recently received orphan drug
designation from the FDA, and the Company expects to file its first
IND in 2020. In order to support its plan to initiate multiple
IND-track programs, the Company is providing access to its ExVive™
in vitro tissue disease modeling platform to facilitate high value
drug discovery and development collaborations. Organovo’s
wholly-owned subsidiary, Samsara Sciences, provides the Company and
its clients with high quality human liver and kidney cells for
research applications. Organovo is changing the shape of life
science research and transforming medical care. Learn more at
www.organovo.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements regarding the potential benefits and
therapeutic uses of the Company’s therapeutic liver tissue,
including the benefits of an orphan designation; the Company’s
expectations regarding the FDA regulatory pathway and anticipated
timelines for its regulatory filings; the potential market
opportunity for the Company’s therapeutic tissue candidates; and
customer demand for and acceptance of its disease modeling and
other in vitro tissue platforms. The factors that could cause the
Company's actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the possibility that the final results of
the Company's preclinical studies may be different from the
Company's studies or interim preclinical data results and may not
support further clinical development of its therapeutic tissues;
the Company may not successfully complete the required preclinical
and clinical trials required to obtain regulatory approval for its
therapeutic tissues on a timely basis or at all; risks that
competitive products may adversely impact the market opportunity
for the Company’s therapeutic tissue candidates; the Company's
ability to develop, market and sell products and services based on
its technology; the expected benefits and efficacy of the Company's
products, services and technology; the Company’s ability to execute
framework agreements involving multi-year commitments and routine
use on a timely basis, or at all; the Company’s ability to
successfully complete studies and provide the technical information
required to support market acceptance of its products, services and
technology, on a timely basis or at all; the Company's business,
research, product development, regulatory approval, marketing and
distribution plans and strategies, including its use of third party
distributors; the Company’s ability to recognize deferred revenue;
and the Company’s ability to meet its fiscal-year 2019 goals and
outlook. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including its
Annual Report on Form 10-K filed with the SEC on May 31, 2018. You
should not place undue reliance on these forward-looking
statements, which speak only as of the date that they were made.
These cautionary statements should be considered with any written
or oral forward-looking statements that the Company may issue in
the future. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these
statements to reflect actual results, later events or circumstances
or to reflect the occurrence of unanticipated events.
Investor & Press Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jul 2023 to Jul 2024